High-throughput screening-driven lead discovery: Meeting the challenges of finding new therapeutics

Research output: Contribution to journalReview article

52 Scopus citations


The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.

Original languageEnglish (US)
Pages (from-to)487-494
Number of pages8
JournalCurrent Opinion in Drug Discovery and Development
Issue number4
StatePublished - Jul 1 2005



  • ADME
  • High-throughput screening
  • Lead discovery
  • Medicinal chemistry
  • Toxicology
  • Virtual screening

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this